Virma-flox Mouse

VIRMA, also known as KIAA1429, is a key component of the m6A methyltransferase complex. N6 -methyladenosine (m6A) is a prevalent eukaryotic mRNA modification that regulates various biological processes like tissue development, stem cell formation, and cancer development. VIRMA is involved in guiding region-selective m6A methylation, particularly in the 3'untranslated region (3'UTR) and near stop codons of mRNAs, and is associated with alternative polyadenylation [1].

In multiple cancer types, VIRMA has shown oncogenic properties. In nasopharyngeal carcinoma, it promotes tumorigenesis and metastasis by upregulating E2F7 in an m6A-dependent manner [2]. In breast cancer, it facilitates cancer progression through m6A-dependent cytosolic HAS2 stabilization [3]. In triple-negative breast cancer, VIRMA promotes disease progression by increasing m6A-dependent KIF15 expression [4]. In non-small cell lung cancer, VIRMA-guided m6A modifications promote cancer progression via m6A-dependent degradation of DAPK3 mRNA [6]. In intrahepatic cholangiocarcinoma, VIRMA stabilizes TMED2 and PARD3B expression through an m6A-HuR-mediated mechanism, promoting cancer cell proliferation and metastasis [5].

In conclusion, VIRMA is a crucial regulator in the m6A mRNA methylation process, playing significant roles in cancer development and progression. Studies using in vitro and in vivo models, including gene-knockdown experiments, have revealed its oncogenic functions in multiple cancer types, highlighting its potential as a therapeutic target for cancer treatment.